| Migraine Disorders
Ajovy vs Zavzpret
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Ajovy vs Zavzpret with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZavzpret has a higher rate of injection site reactions vs Ajovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zavzpret but not Ajovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ajovy
Zavzpret
At A Glance
SC injection
Monthly or every 3 months
CGRP antagonist
Intranasal
As needed
CGRP receptor antagonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 225 mg SC monthly or 675 mg SC quarterly (three consecutive 225 mg injections) into abdomen, thigh, or upper arm.
Episodic migraine Pediatric patients 6 to 17 years weighing 45 kg or more: 225 mg SC monthly.
Migraine Disorders 10 mg as a single spray in one nostril as needed; maximum 10 mg (one spray) per 24-hour period; safety of treating more than 8 migraines in a 30-day period has not been established.
Contraindications
- Serious hypersensitivity to fremanezumab-vfrm or any excipient, including anaphylaxis and angioedema
- History of hypersensitivity reaction to zavegepant or any component of ZAVZPRET, including anaphylaxis
Adverse Reactions
Most common (>=2%) Injection site reactions (pain, induration, erythema)
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylactic reactions, angioedema, hypertension, Raynaud's phenomenon
Most common (>=2%) Taste disorders (dysgeusia, ageusia), nausea, nasal discomfort, vomiting
Serious Hypersensitivity including facial swelling and urticaria (less than 1%)
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Pharmacology
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby inhibiting CGRP-mediated signaling implicated in migraine.
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ajovy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (7/12) · Qty limit (10/12)
Zavzpret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Ajovy
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Zavzpret
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Ajovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zavzpret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availablePAF Co-Pay Relief: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZavzpretView full Zavzpret profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.